It depends on the outcome. Both parties believe there is value in the Daptomycin license from what I have seen. If the arbitration result is big enough in favour of POH, it may be worth bargaining to move forward with bringing Daptomycin to market at Mylan's expense.
Mylan arbitration, page-325
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $9.508M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $1.2K | 316K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 49 | 71291001 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 38947842 | 19 |
View Market Depth
| Last trade - 10.12am 21/05/2024 (20 minute delay) ? |
| AVE (ASX) Chart |